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RESEARCH ARTICLE
Neuroinflammatory Markers Associate
with Cognitive Decline after Major
Surgery: Findings of an Explorative Study
Mattias Danielson, MD ,1 Andreas Wiklund, MD, PhD,2,3 Fredrik Granath, PhD,4
Kaj Blennow, MD, PhD,5,6 Souren Mkrtchian, PhD,2 Bengt Nellgård, MD, PhD,1
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Sven-Erik Ricksten, MD, PhD,1 and Lars I. Eriksson, MD, PhD, FRCA2,7
Objective: Long-term cognitive decline is an adverse outcome after major surgery associated with increased risk for mortal-
ity andmorbidity. We studied the cerebrospinal fluid (CSF) and serum biochemical inflammatory response to a standardized
orthopedic surgical procedure and the possible association with long-term changes in cognitive function. We hypothesized
that the CSF inflammatory response pattern after surgery would differ in patients having long-term cognitive decline defined
as a composite cognitive z score of ≥1.0 compared to patients without long-term cognitive decline at 3months postsurgery.
Methods: Serum and CSF biomarkers of inflammation and blood–brain barrier (BBB) integrity were measured preoper-
atively and up to 48 hours postoperatively, and cognitive function was assessed preoperatively and at 2 to 5 days and
3 months postoperatively.
Results: Surgery was associated with a pronounced increase in inflammatory biomarkers in both CSF and blood throughout
the 48-hour study period. A principal component (PC) analysis was performed on 52 inflammatory biomarkers. The 2 first PC
(PC1 andPC2) construct outcome variables on CSF biomarkers were significantly associatedwith long-term cognitive decline
at 3 months, but none of the PC construct serum variables showed a significant association with long-term cognitive decline
at 3 months. Patients both with and patients without long-term cognitive decline showed early transient increases of the
astroglial biomarkers S-100B and glial fibrillary acidic protein in CSF, and in BBBpermeability (CSF/serum albumin ratio).
Interpretation: Surgery rapidly triggers a temporal neuroinflammatory response closely associated with long-term cog-
nitive outcome postsurgery. The findings of this explorative study require validation in a larger surgical patient cohort.
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Long-term decline in cognitive capacity is a fearedadverse outcome after surgery, affecting 10 to 20% of
elderly surgical patients and associated with increased risk
for mortality and morbidity.1–4 Recent advances in experi-
mental and translational human models point toward a
critical role for the innate immune system behind this
long-term impact on higher brain functions.5,6
Surgical trauma triggers the innate immune system
to launch a systemic inflammatory response orchestrated
by humoral and cellular inflammatory mediators that ulti-
mately promote healing and restoration of homeostasis.
Although initiated locally by damage-associated molecular
patterns (DAMPs), the immune response to trauma is rap-
idly transmitted systemically to remote organs by humoral
mediators and by activated peripheral immune cells.
Despite the classical view of the brain as an immune-
privileged organ, there is a growing body of evidence that
the central nervous system (CNS) is impacted by surgical
trauma by inflammatory mediators rapidly reaching the
brain via cellular and humoral signaling, facilitated by a
transient increase in blood–brain barrier (BBB) permeabil-
ity.5 Activation of the CNS immune system by surgery
and tissue damage is a hallmark of sickness syndrome
being proposed to further develop to cognitive decline
postsurgery, especially in the elderly.1,3,4
A series of studies in humans suggests that surgery is
followed by a rapid (within 4–8 hours) elevation in cerebrospi-
nal fluid (CSF) inflammatory, astroglial, neuronal degenera-
tive, and injury biomarkers7–11 with simultaneous signs of
BBB damage8,12 along with transient increase in systemic con-
centrations of neurodegenerative and brain injury biomarkers
(tau and neurofilament light).13 Recent positron-emission
tomography (PET) findings among surgical patients have fur-
thermore uncoveredmarked changes in brain immune activity
with an association between long-term upregulation of human
brain immune activity postsurgery and a simultaneous reduc-
tion in higher cognitive brain functions.14
In this explorative study, we mapped the immediate
temporal CSF and serum biochemical inflammatory
response trajectory to a standardized surgical procedure
and explored the potential association between a temporal
molecular pattern and long-term changes in cognitive
function. We hypothesized that the individual CSF
inflammatory response trajectory after surgery would differ
in patients with, versus those without, long-term postoper-
ative cognitive decline.
Patients and Methods
Participants and Study Design
This study complies with the 2013 Declaration of Helsinki.
The Regional Ethics Committee in Stockholm, Sweden,
approved the study protocol (Dnr 2013/2297-31/4 and
2014/834-32), and the study was registered at www.
clinicaltrials.gov (identifier NCT02759965).
Between September 2014 andMarch 2016, we included
34 patients scheduled for elective total hip or knee replacement
surgery in this prospective observational clinical trial at
Karolinska University Hospital, Stockholm (n = 14), and
Sahlgrenska University Hospital, Mölndal (n = 20), after
obtaining signed informed and written consent. Exclusion
criteria included preexisting neurological, psychiatric, or clini-
cally evident neurovascular disease, recent or ongoing treat-
ment with anti-inflammatory drugs, severe organ failure
(eg, cardiac, renal, or hepatic), coagulopathy, alcohol or drug
abuse, poorly controlled diabetes mellitus, or autoimmune dis-
ease. Patients with preoperative cognitive impairment,
corresponding to a Mini-Mental State Examination score of
<24, were excluded. Prior to anesthesia induction, a polyamide
lumbar intrathecal catheter (Perifix epidural catheter; Braun,
Melsungen, Hessen, Germany) was inserted using an 18-gauge
Tuohy needle. Spinal anesthesia was induced with 10 to 15mg
bupivacaine (Marcain Spinal; Astra-Zeneca AB, Södertälje,
Sweden) and 5 to 10μg sufentanil (Sufenta; Janssen-Cilag AB,
Solna, Sweden) administered via the intrathecal catheter and
supplemented with light intravenous (IV) propofol sedation
(Propolipid; Fresenius Kabi AB, Uppsala, Sweden) in IV bolus
doses of 10 to 30mg or an infusion at a rate of 0.5 to 2mg/kg/
h. None of the patients received oral or IV anti-inflammatory
and psychoactive drugs intraoperatively. Six patients (22%)
received subcutaneous ketorolac 15 to 30mg intraoperatively
as part of the postoperative pain regimen.
The intrathecal catheter was left in place for
48 hours. Preoperatively and at 4, 8, 24, 32, and 48 hours
after skin incision, serial CSF (5ml) and blood samples
(20 ml) were collected and subsequently centrifuged,
aliquoted, and stored at −80C for offline analysis.
CSF and Serum Biomarkers of Systemic and
Neuroinflammation
CSF and serum samples were analyzed using a high-
throughput, multiplex immunoassay analysis (Proseek
Multiplex, Proximity Extension Assay technology, Inflam-
mation 1 panel; Olink, Uppsala, Sweden). This panel was
compiled to detect established and exploratory biomarkers
of inflammation. Oligonucleotide-labelled antibody probe
pairs were allowed to bind to their respective target pro-
tein present in the sample. A polymerase chain reaction
(PCR) reporter sequence was formed by a proximity-
dependent DNA polymerization event, amplified, and
subsequently detected and quantified using real-time
PCR. Analyzed proteins are described in Supplementary
Table 1. Values of the various inflammatory variables are
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presented as an arbitrary unit in log2 scale and can thus
be used only for relative changes of the same protein.
CSF and Serum Biomarkers of Astroglial Injury
and BBB Dysfunction
Measurements of the astroglial injury markers S-100B (CSF,
serum) and glial fibrillary acidic protein (GFAP; CSF) were
performed by an electrochemiluminescence immunoassay
and enzyme-linked immunosorbent assay,15 respectively, and
albumin levels in CSF and serum were measured by
immunonephelometry.
Neurocognitive Testing
Neurocognitive capacity was assessed using the Interna-
tional Study of Postoperative Cognitive Dysfunction test
battery4 1 to 2 weeks prior to surgery, at discharge from
the hospital (2–5 days after surgery), and at 3 months
after surgery. In brief, this test battery measured cognitive
performance using 4 different tests, providing 7 variables
for analysis.4 Changes in cognitive performance were cal-
culated as previously described4 for each of 7 test variables
and corrected for practice effects and variability using data
from an age-matched control group who underwent test-
ing using the same battery and with the same intervals.
To quantify the change from preoperative to postoperative
tests, z scores were calculated for each variable. We
defined long-term cognitive decline as a composite z score
of ≥1.0 at 3 months postsurgery (poor neurocognitive out-
come group), and those without had a composite z score
of <1.0 (good neurocognitive outcome group).
Sleep, Pain, and Delirium Assessment
A visual analog scale (VAS) expressed as a 10-point scale was
used to assess quality of sleep and the severity of postopera-
tive pain at regular intervals after surgery. Delirium was
assessed 24 and 48 hours postoperatively using the confusion
assessment method for the intensive care unit (CAM-ICU).16
Statistical Analysis
The sample size calculation was based on the hypothesis that
there is a significant association between the postoperative
cytokine concentration in CSF and a change in cognitive
function, expressed as the combined z score at the first postop-
erative test. We assumed that the correlation coefficient would
be approximately 0.5 for the association between CSF IL-6
concentration and the z score, which would require 25 patients
to obtain a power of 80%. Because of the risk of incomplete
data sets or dropouts, we aimed to enroll >30 patients.
The effects of surgery on changes in CSF and serum
biomarkers from preoperative levels were tested by a
repeated measurements analysis of variance, and paired
t tests were used to assess significant changes from preop-
erative levels at each postoperative time point. We
performed a principal component analysis (PCA) on the
preoperative CSF and blood biomarker measurements.
Fifty-two of 92 markers, for which less than 25% of the
subjects’ preoperative measurements were at the lower
detection limit, were included in the PCA.
In brief, a principal component (PC) can be seen as
a weighted average of the Z-transformed measurements of
all 52 markers:
PC =
X52
1
wi ×Zi,whereZi
=Xi−
X
SD
andwi is the weights obtained from the PCA
Because the Zi’s have means that equal zero, the PC
also has mean of zero and a standard deviation (SD)
depending on the weights (wi). The weights reflect the
PC’s correlation to each of the individual markers, where
large positive and negative weight implies positive and
negative correlation, respectively.
Analysis of the Postoperative Outcome
The 3 first PCs from the preoperative PCA were a priori
selected as primary outcome variables. Postoperative out-
come variables were then created by applying these weights
on the Z-transformed markers at each postoperative time
point for each variable. These longitudinal outcome vari-
ables were analyzed by a random slope and random inter-
cept repeated measurement model with an unstructured
covariance matrix. This model included the preoperative
value of the PC as a covariate, and the group–time interac-
tion was assessed to test a difference in the time course for
patients with or without long-term cognitive decline. The
analyses of individual CSF and blood biomarkers were car-
ried out with a similar model, with the exception that time
was considered as a categorical variable. Complementary to
the group–time interaction test, a Fisher exact test was
applied to compare proportions with positive slopes in the
PC2 analysis with respect to cognitive outcome.
As a sensitivity analysis, we randomly divided the
patients into 12 subsets and repeatedly performed PCAs by
leaving out 1 subset at a time. The PC2 from each analysis
was then applied to the postoperative measurement for all
patients, and the time course for the 2 patients left out from
each PCA was compared to the time course obtained from
the PC2 based on all patients. Furthermore, the group–time
interaction tests from each of the 12 analyses were performed
(Supplementary Table 2). Differences between groups at the
various time points, postoperatively, were tested by t test, all-
owing for unequal variances between groups in cases when
applicable. Bonferroni–Holm correction was applied when
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testing differences in preoperative levels for individual CSF
and blood biomarkers with respect to long-term cognitive
outcome and for tests of group–time interactions for individ-
ual blood biomarkers. Postoperative longitudinal changes of
the biomarkers of astroglial injury and the CSF/serum albu-
min ratio were analyzed statistically with a linear mixed
model, using an autoregressive covariance matrix and random
intercept, comparing changes from baseline over time after
surgery and the group–time interaction. A 2-way analysis of
variance for repeated measurements was used for analysis of
quality of sleep and the severity of postoperative pain (VAS).
All data on pre- and intraoperative patient characteristics are
presented as median and interquartile range (Q1, Q3). Data
on biomarkers are presented as means and standard error of
the mean (SEM) and group differences tested by Mann–
Whitney U test and Fisher exact test. A p < 0.05 was consid-
ered significant. The analyses were performed by PROC
PRINCOMP, PROC MIXED, and PROC TTEST with
software SAS version 9.4 (SAS Institute, Cary, NC).
Results
The clinical trial profile is shown in Figure 1. Out of
156 patients assessed for eligibility, 34 patients entered the
study. Of these, 7 patients were excluded for reasons
described in Figure 1, providing 27 patients for final analysis.
Neurocognitive Outcomes and Perioperative
Patient Characteristics
At 3 months postsurgery, 6 of 27 (22%) showed a compos-
ite z score of ≥1.0 (poor neurocognitive outcome group,
n = 6), among which 2 had a composite z score of >1.96.
The remaining 21 patients (78%) had a composite z score of
<1.0 (good neurocognitive outcome group, n = 21).
At hospital discharge (3–5 days postsurgery), 21 patients
(78%) showed a composite z score of ≥1.0, among which
FIGURE 1: CONSORT (Consolidated Standards of Reporting Trials) diagram showing patient inclusion.
FIGURE 2: Individual (n = 27) neurocognitive outcome
trajectories at hospital discharge (postoperative day 3–5) and
at 3 months after major surgery. At 3 months postsurgery,
6 of 27 patients (22%) showed a composite z score of ≥1.0
(long-term cognitive decline).
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13 patients (48%) had a composite z score of >1.96. Individ-
ual neurocognitive trajectories are presented in Figure 2.
Patient demographics and comorbidities are pres-
ented in Table 1. There were no differences between
patients in the good versus poor neurocognitive outcome
groups with respect to demographic variables, comorbidity
burden, American Society of Anesthesiologists physical
status classification, preoperative hemoglobin, serum creat-
inine, or ongoing medication. Perioperative patient char-
acteristics are described in Table 2.
TABLE 1. Demographic and Comorbidity Characteristics by Neurocognitive Outcome at 3 Months
Characteristics
Good Neurocognitive
Outcome, n = 21
Poor Neurocognitive
Outcome, n = 6 p
Age, yr 71 (65–76) 68 (65–71) 0.32
Sex, male, n (%) 8 (38) 1 (17) 0.63
Weight, kg 80 (73.5–89) 79 (75–88.5) 0.93
Height, cm 171 (167–179) 166 (163–175) 0.24
Body mass index, kg/m2 26.7 (24.6–29.4) 27.9 (25.7–31.5) 0.44
Comorbidity
Hypertension, n 11 4 0.66
Diabetes mellitus, type 1, n 2 0 1
Diabetes mellitus, type 2, n 0 1 0.22
History of myocardial infarction, n 1 0 1
Active smoker, n 0 0 NA
ASA classification 0.197
I, n 7 0 —
II, n 13 6 —
III, n 1 0 —
IV, n 0 0 —
Blood hemoglobin, g/l 138 (128–147) 143 (134–157) 0.41
Serum creatinine, μmol/l 71 (62–89) 68 (47–96) 0.63
Preoperative WBC count 6.3 (5.4–7.9) 7.7 (6.5–8.7) 0.22
Ongoing medication
Beta-adrenergic blocker, n 3 1 1
Calcium channel blocker, n 4 3 0.29
Angiotensin converting enzyme inhibitor, n 7 0 0.15
Angiotensin II receptor antagonist, n 4 2 0.59
Insulin + oral antidiabetic, n 2 0 1
Oral antidiabetic, n 0 1 0.22
Acetaminophen, n 6 2 1
Opioids, n 0 0 NA
Values are median (Q1–Q3). Group differences tested by Mann–Whitney U test and Fisher exact test.
ASA = American Society of Anesthesiologists; NA = not applicable; WBC = white blood cell.
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TABLE 2. Perioperative Patient Characteristics by Neurocognitive Outcome at 3 Months
Characteristics
Good Neurocognitive
Outcome, n = 21
Poor Neurocognitive
Outcome, n = 6 p
Intraoperative
Propofol, mg 170 (80–291) 168 (75–288) 1.0
Fentanyl, n 4 0 0.55
Alfentanil, n 2 0 1.0
Ketorolac, local infiltration, n 5 1 1.0
Vasopressor, n 12 5 0.36
Intravenous fluids, ml 1,200 (950–1,350) 925 (750–1,560) 0.44
Blood transfusion, n 0 1 0.22
Duration of procedure, min 89 (72–102) 86 (72–101) 0.93
Procedure, n
Hip replacement 14 5 0.63
Knee replacement 7 1 0.63
Bleeding, ml 300 (150–450) 225 (150–550) 1.0
Postoperative, 24 h
PACU length of stay, min 165 (98–225) 171 (128–579) 0.47
Intravenous fluids, ml 1,000 (750–1,850) 1,575 (260–2,500) 0.48
Medication, n
Gabapentin 6 2 1
Oral opioid 20 6 1
Intravenous opioid 13 3 0.66
Pain assessment, VAS score 0.09
4 h 1 (0–4) 0 (0–4) —
8 h 6 (4–8) 6 (3–7) —
24 h 6 (5–8) 6 (5–8) —
32 h 5 (3–7) 8 (6–8) —
48 h 4 (2–5) 6 (6–8) —
Sleep assessment, VAS score 0.92
24 h 5 (3–7) 5 (3–9)
48 h 3 (2–6) 5 (3–6) —
Postspinal puncture headache, n 0 1 0.22
Blood patch, n 0 1 0.22
Values are median (Q1–Q3). Group differences tested by Mann–Whitney U test and Fisher exact test. A 2-way analysis of variance for repeated mea-
surements was used to assess differences between groups with respect to quality of sleep and the severity of postoperative pain (VAS).
PACU = postanesthesia care unit; VAS = visual analog scale.
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There were no differences between the 2 neurocognitive
outcome groups with respect to administration of sedatives,
vasoactive drugs, fluid management, intraoperative bleeding,
duration and type of procedure, or length of stay in the post-
anesthesia care unit. The VAS score for assessment of pain
and sleep quality did not differ between the 2 groups, and no
patient developed postoperative delirium.
The use of ketorolac was evenly distributed between
the groups with good (24%) and poor (17%) neurocognitive
outcome (see Table 2).
One patient with long-term cognitive decline devel-
oped postspinal headache and was successfully treated with
an epidural blood patch.
CSF and Serum Biomarkers of Inflammation
Twenty-eight CSF and 14 serum biomarkers had a high
fraction of measurements lower than detection limit and
were not further analyzed. Supplementary Table 3 displays
data on 64 CSF and 76 serum biomarkers irrespective of
neurocognitive outcomes. Forty-seven CSF (73%) and
62 (79%) serum biomarkers showed overall significant
48-hour postsurgery changes from baseline (ie, a signifi-
cant time effect), and many of the remaining markers
showed a significant change from baseline on at least
1 postoperative time point (see Supplementary Table 3).
CSF and Serum Biomarker Response to Surgery
in Patients with Good versus Poor Postoperative
Neurocognitive Outcome
Out of 27 patients enrolled, 3 patients lacked 1 or more post-
operative CSF samples, thus analysis of inflammatory bio-
markers was performed in 24 patients. At first, preoperative
CSF and serum biomarker levels were analyzed to explore the
association between preoperative levels of inflammatory mol-
ecules and neurocognitive outcomes at 3 to 5 days and at
3 months postsurgery. After correction for multiple compari-
sons, none of the detectable inflammatory biomarkers mea-
sured preoperatively in either CSF or blood showed an
FIGURE 3: Preoperative principal components (PCs) 1–3 based on all 52 inflammatory biomarkers as construct postoperative
outcome variables assessing the group–time interaction in cerebrospinal fluid (CSF) and serum (n = 24). The 2 first PC (PC1 and
PC2) construct outcome variables on CSF samples were significantly associated with long-term cognitive decline at 3 months
(poor). CSF biomarkers of inflammation increased the first 48 hours after surgery in the poor neurocognitive outcome group,
and the opposite was seen in the good neurocognitive outcome group. In the corresponding analyses based on serum, none of
the 3 PC-construct variables show a significant association to poor neurocognitive outcome.
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association with neurocognitive outcomes at 3 to 5 days or
3 months (Bonferroni–Holm correction).
To overcome a potential mass-significance problem
when assessing the relationship between temporal changes of
biomarkers in CSF and serum to neurocognitive outcomes,
as the next step, a PCA was performed on the preoperative
measurements, irrespective of neurocognitive outcomes. The
PCA was performed on the subset of 52 CSF markers for
which at least 75% of the subjects had a preoperative value
above the lower detection limit. Based on the loadings for the
first 3 PCs, explaining 63% of the preoperative biomarker
variation (that is, 49%, 8%, and 6% for PC1–PC3, respec-
tively), 3 time-dependent outcome variables were created
(PC1–PC3). For the 2 first of these construct outcome vari-
ables (PC1 and PC2), the overall time course patterns of the
biomarkers were significantly different with respect to
neurocognitive outcomes after 3 months (Fig 3; group–time
interaction: p = 0.02, p = 0.00005, and p = 0.76 for PC1–
PC3, respectively). All 6 patients with long-term cognitive
decline showed an increase over time for the PC2 constructed
outcome variable, but such an increase was detected in only
3 out of 18 patients without long-term cognitive decline
(100% vs 17%, p = 0.006; Fig 4). For the same PCA con-
struct variables, we could not detect any association with
neurocognitive outcomes at days 3 to 5 postsurgery.
In a corresponding PCA on the same biomarkers in
serum samples, the 3 first components explained 39% of
the preoperative biomarker variability (18%, 11%, and
10% for PC1–PC3, respectively). None of these 3 PC
construct variables in serum was significantly associated
with neurocognitive outcome (see Fig 3; group–time
interaction: p = 0.48, p = 0.29, and p = 0.63 for PC1–
PC3, respectively).
In the sensitivity analyses, the time courses obtained
when the subsets of patients were left out from the PCAs
were virtually unchanged compared to the results based
on all patients, and the group–time interaction tests based
on the 12 data sets were all statistically significant (see
Supplementary Table 2).
The relative contribution of individual biomarkers to
the separation of the 2 CSF inflammatory trajectories was
analyzed (Supplementary Table 4). When exploring the time
dependence of individual cytokines and chemokines, IL12B,
IL18, IL6, IL8, TGFB1, and TNFRSF9 showed a significant
time–group interaction, and 10 out of 16 chemokines dis-
played a significant time–group interaction. Two out of
6 neurotrophic/growth factors (HGF, NGF), CDCP1,
EIF4EBP1, MMP1, and 1 leukocyte cell surface biomarker
(CD244) showed a significant time–group interaction. Only
3 of the individual serum biomarkers (LIF, TNFRSF11B,
FIGURE 4: Individual regressions for the second principal component (PC2) based on all 52 cerebrospinal fluid (CSF) markers
(n = 24). Individual regressions for PC2 construct outcome variables revealed that all patients with long-term cognitive decline
(blue, n = 6) showed an increased CSF inflammatory trajectory over time, but only 3 of 18 patients without long-term cognitive
decline (red, n = 18) showed this inflammatory CSF trajectory (p = 0.006; Z indicates individual z score).
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and CCL23) showed nominally significant group–time inter-
action, and only LIF was significant after Bonferroni–Holm
correction (p < 0.05).
Initial and Late Temporal CSF Biomarker
Responses to Surgery in Patients with and
without Long-Term Cognitive Decline
In a detailed analysis, the biomarker time-course patterns
for PC1 showed a differential trajectory initially after sur-
gery with respect to the development of long-term cogni-
tive decline. The majority of the PC1 loadings had
approximately equal size, and, as shown in Supplementary
Table 4, for the vast majority of the biomarkers the
response to surgery in the early phase (ie, the difference
between 4 and 8 hours and baseline) was lower in the
group with long-term cognitive decline (see Supplemen-
tary Table 4). Even though this pattern was consistent,
only a few individual markers (12/52) showed a nominally
significant difference between the groups (indicated by
asterisks on the sign).
Time-course patterns for the highly significant PC2
showed the reverse pattern, with a pronounced difference in
the end of the observation period (32 and 48 hours post-
surgery). This was supported by the significantly higher late
response in the group with long-term cognitive decline for
markers with high PC2 loadings, for example, IL6, IL8,
CCL3, CCL8, and CXCL6, as seen in Supplementary
Table 4 and in Figure 5. In addition to biomarkers with high
PC2 loadings, we detected additional biomarkers with signifi-
cant separation at 48 hours between patients in the good ver-
sus poor neurocognitive outcome groups (IL12B, IL18,
TGFB1, CCL3, CCL8, CXCL5, CXCL6, and HGF; see
Supplementary Table 4).
Pathway Analysis
CSF biomarkers either with the highest loadings in PC2
or with significant separation between the good and poor
neurocognitive outcome groups at 48 hours were analyzed
for the enrichment in biological signaling pathways with
online tools using Kyoto Encyclopedia of Genes and
Genomes (KEGG) and WikiPathways databases, as well
as Ingenuity Pathway Analysis software (Qiagen, Hilden,
Germany). All database analyses produced similar results
FIGURE 5: Postoperative changes in cerebrospinal fluid (CSF) levels of 2 cytokines (IL6 and IL8) and 3 chemokines (CCL3, CCL8,
and CXCL6) with respect to neurocognitive outcome (n = 24). In patients with good neurocognitive outcome at 3 months,
increased CSF levels of the biomarkers were seen 4 to 8 hours after surgery followed by a resolution at 32 and 48 hours. In
contrast, in patients with long-term cognitive decline, CSF biomarker levels increased over time and were higher at the later
phase (32 and 48 hours) postsurgery compared to patients without long-term cognitive decline (good). *p < 0.05, **p < 0.01,
(*)p < 0.1. Data are presented as mean  standard error of the mean.
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and showed particularly strong associations of chemokine
signaling, cytokine–cytokine receptor interaction, and toll-
like receptor signaling pathways with long-term cognitive
decline. This is consistent with the overrepresentation of
the chemokines in the group of high PC2 loadings
biomarkers.
CSF and Serum Markers of Astroglial Injury and
BBB Function
Serum S-100B showed a transient increase at 4 and 8 hours
postoperatively (p < 0.001), and a similar pattern was noted
in CSF (p = 0.028). There was also a transient increase in
CSF levels of GFAP (p = 0.005) and BBB permeability
(expressed as CSF/serum albumin ratio) at 4 and 8 hours
postsurgery (p = 0.013). None of these changes in CSF or
serum were associated with neurocognitive outcomes at 3 to
5 days or 3 months postsurgery.
Discussion
The major finding of this explorative study was that the
time course of levels of inflammatory biomarkers in CSF
differed between patients with cognitive decline at
3 months postsurgery and patients without cognitive
decline. In the latter group, an initial early (4–8 hours)
increase in CSF biomarkers of inflammation was followed
by a gradual decline. In contrast, a divergent temporal
pattern was uncovered in patients developing long-term
cognitive decline; in these patients, an initial relative
decline in CSF markers of inflammation was followed by
continuous increase of inflammatory biomarkers through-
out the 48-hour study period. In contrast, corresponding
analyses of serum biomarkers showed poor association
with long-term cognitive outcomes.
To our knowledge, this is the first study that describes
an acute CSF inflammatory biomarker pattern in response to
major surgery that closely associates with long-term cognitive
outcomes. Our data suggest that preoperative levels of inflam-
matory molecules in either CSF or blood have little impact
on neurocognitive outcomes, as there was no association
between levels of cytokines and chemokines prior to surgery
and later changes in individual cognitive performance. This
may preclude preoperative assessment of baseline biomarker
patterns as preventive strategy.
The separation between inflammatory trajectories
rapidly becomes apparent once surgery has triggered the
innate immune system and reached the CNS. Notably,
the data display a very robust difference in the biomarker
response pattern in CSF in relation to long-term
neurocognitive outcome. Our findings also suggest that
long-term brain outcomes are dependent on mechanisms
related to inflammatory resolution, which seems critical
for the recovery of cognitive capacity.
FIGURE 6: Temporal changes in cerebrospinal fluid (CSF) and serum markers of astroglial injury and blood–brain barrier function
after major surgery (n = 27). The astroglial biomarker S-100B showed a transient increase at 4 and 8 hours postoperatively both
in serum and CSF. At 24 hours postoperatively, both CSF and serum S100B were normalized. There was also a transient increase
in CSF levels of glial fibrillary acidic protein (GFAP) and increased blood–brain barrier permeability (CSF/serum albumin ratio) at
4 and 8 hours postsurgery. There was no association between these changes in astroglial injury biomarkers or the CSF/serum
albumin ratio and neurocognitive outcomes at 3 months postsurgery. Data are presented as mean  standard error of the mean.
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A small number of CSF cytokines, inflammatory
cell-mediated biomarkers, and a broader array of
chemokines contributed significantly to the differential
response pattern in CSF. Common denominators for the
biomarkers showing high PC loadings and significant dif-
ferences between the 2 patient groups at the early and/or
late time points are their chemo-attractive and
differentiation-inducing features on innate immune cells,
that is, myeloid cells and polymorphonuclear cells. In
patients with long-term cognitive decline, higher CSF
levels of IL-6, IL-8, CCL3, CCL8, and CXCL6 at
48 hours after surgery (see Fig 5), a time point when the
BBB permeability had returned to presurgery status
(Fig 6), suggest that immune cells within the CNS pro-
duce these mediators. Furthermore, the significant contri-
bution from CX3CL1 (fractalkine), a neuron-enriched
biomarker, during the first 8 hours suggests early neuronal
involvement (see Supplementary Table 4). IL-6 has, in
addition to its multiple inflammatory functions, also been
described as causing reduced hippocampal neurogenesis in
rodent models. Inhibitors of IL-6 are clinically available,
both as an antibody binding to sIL-6R and thereby
inhibiting IL-6 signaling and as a small molecule
inhibiting JAK/STAT signaling, resulting in less IL-6 pro-
duction. It is tempting to speculate that such anti-
inflammatory treatment immediately after surgery could
affect the long-term cognitive outcome.
Major surgery is accompanied by increased CSF
levels of astroglial cell injury markers, for example, GFAP
and S-100B,8 and short-lasting alterations of BBB perme-
ability, as assessed by an increase in the CSF/serum albu-
min ratio.8,9 Those findings were confirmed in the present
study, suggesting a surgery-induced astroglial injury and
increased BBB permeability (see Fig 6). However, neither
the CSF release of the astroglial injury markers nor the
increased BBB permeability was associated with long-term
cognitive decline; therefore, we propose that this condition
is not primarily ascribed to a more pronounced disruption
of the BBB integrity.
Although Hirsch et al7 found substantial increases in
CSF and blood concentrations of proinflammatory cyto-
kines during the first 18 hours postsurgery, they were
unable to detect an association with changes in cognitive
outcomes at 1 to 3 days postsurgery. In line with these
observations, we confirmed that there was no association
between either CSF or serum biomarker patterns and early
neurocognitive outcomes at 3 to 5 days postsurgery, indi-
cating that other factors that adversely affect cognitive per-
formance in the immediate (1–3 days) postoperative
period such as postoperative pain, sleep disturbances, and
drug effects17 are more important. In a recent PET study
of the human brain after surgery, an early and profound
downregulation of the brain immune activity was demon-
strated followed by a recovery at 3 months, and in some
patients an increase above baseline was observed,
suggesting a late upregulation of the immune activity.14
The magnitude of this upregulation correlated to the
decline in some aspects of the cognitive function. The pre-
sent results are in line with these findings; patients having
a poor cognitive performance at 3 months display steadily
increased levels of CSF biomarkers of inflammation in
contrast to those patients with recovered cognitive
function.
Interestingly, although a close association between
CSF biomarker pattern and long-term neurocognitive out-
comes was found, there was no support for a difference in
the trajectories of the systemic inflammatory response
between patients with good versus poor neurocognitive
outcome. This finding may be due to a limited power to
detect a differential trajectory within the systemic circula-
tion, or it might indicate that other systemic conditions
are important determinants of biomarker concentrations
in blood after a surgical trauma. These results are in line
with a recent meta-analysis on the association between
peripheral inflammatory markers and postoperative cogni-
tive dysfunction showing that plasma IL6, but no other
peripheral cytokine, was associated with postoperative cog-
nitive dysfunction.18 Moreover, our findings confirm
recent findings by Forsberg et al14 of a lack of association
between changes in plasma cytokines postsurgery and cog-
nitive performance. Hence, it may be argued that the use
of plasma measurements of acute inflammatory markers in
the early postoperative period (hours) may have a limited
utility for prediction of late postoperative neurocognitive
decline. However, we cannot exclude the possibility that
serial blood measurements of inflammatory biomarkers at
later time points (days to weeks postsurgery) would reflect
long-term neurocognitive outcomes.
PCA was applied to identify a set of new indepen-
dent variables explaining most of the preoperative bio-
marker variability, as analyses of individual biomarkers
would be hampered by mass significance due to the high
dimension of explanatory variables. We chose to analyze
the 3 first PCs, explaining 63% of the total preoperative
biomarker variation in CSF. The obtained PCs are linear
combinations of the standardized biomarker measure-
ments, where the coefficients (often called loadings) for
each biomarker are obtained from the PCA so that the
individual components are statistically independent of
each other. The PCs may represent latent processes caus-
ing correlation between individual biomarkers in absence
of the surgical trauma. By applying the identified PCs to
the postoperative measurements in relation to cognitive
outcome, we hypothesized that the latent structures
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identified would be differentially affected by the surgical
trauma. In this study, PC1 had about equally sized loadings
for the vast majority of the 52 biomarkers included and
thus can be interpreted as the average standardized expres-
sion of all markers. PC2 was most strongly associated with
cognitive outcome and had high positive or negative load-
ings for a limited subset of markers; postoperative separa-
tion of these markers with respect to cognitive outcome
will primarily contribute to the observed separation of PC2.
The significant associations to cognitive outcome found
with the PCA approach was considered as a gatekeeping
test, where we identified 6 primary outcome variables (three
PCs in CSF and blood, respectively). Because the PCA
approach yielded a significant association with postoperative
biomarker expression in CSF, no further adjustment was
made for multiple testing when analyzing individual CSF
biomarkers. The interpretation of these results should there-
fore take into consideration the risk of type 1 and type
2 errors.
A major limitation of the present explorative study is
the small sample size, with only 6 patients in the poor
neurocognitive outcome group. Therefore, the findings of
this study should be considered preliminary and requiring
validation in a larger surgical patient cohort. Despite these
caveats, there were consistent and highly significant qualita-
tive and quantitative differences between the good and poor
neurocognitive outcome groups with respect to the brain
immune response to a standardized elective surgical trauma.
The definition of postoperative decline varies across
studies. We decided to classify patients according to a
composite z score higher than 1, which allowed us to also
include patients with minor deterioration and increased
the number of cases with the outcome of interest.
One could argue that the use of bupivacaine and
sufentanil for spinal anesthesia and the indwelling spinal
catheter may have caused an inflammatory reaction in the
CSF. Although bupivacaine has been shown to exert anti-
inflammatory effects in vitro on inflammation-activated
astrocytes19 and lipopolysaccharide-activated
macrophages,20 the effects of intrathecal sufentanil and IV
sedation with propofol on CSF inflammatory biomarkers
are unknown. The anesthetic regimen was uniform, and it
is therefore unlikely that the different brain immune
responses between the good and poor neurocognitive out-
come groups could be explained by interindividual differ-
ences in the anesthetic management. Furthermore, there
were no differences between the 2 groups with respect to
pre-, intra-, and postoperative characteristics, which all
could have had an influence on postoperative cognitive
function. Finally, it should be acknowledged that
increased blood concentrations of S100B may indicate
potential release from extracerebral sources.
In conclusion, in this explorative study, we have shown
that the trajectory of CNS inflammatory response after sur-
gery differs quantitatively and qualitatively in patients with
postoperative long-term cognitive decline versus those
patients not developing long-term cognitive decline, and no
such association to postoperative cognitive decline was shown
for serum biomarkers of inflammation. These findings
require validation in a larger surgical patient cohort.
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